NRAS and neoplasm: Tumor tissue testing revealed one of the seven mutations of interest (BRAF 1799T>A, 1798_1799delGTinsAA; NRAS 181C>A, 182A>G, 183A>T, 182A>T, 183A>C) in 38/60 (63%) patient samples.